Uncategorized
Glaucoma drugs may be repurposed with sustained-release implants
PRAGUE — Sustained-release implants may offer the opportunity to repurpose glaucoma drugs, overcoming noncompliance issues, according to one specialist speaking at the European Glaucoma Society Congress. James David Brandt, MD, said that intraocular implants are effective and have the advantage of avoiding allergic reactions on the ocular surface. However, there is a small risk of infection related to the injection, and the procedure is not easily reversible. If the patient develops an adverse reaction such as macular edema, surgery is needed to remove the implant.